<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36848564</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Innate immune cell activation causes lung fibrosis in a humanized model of long COVID.</ArticleTitle><Pagination><StartPage>e2217199120</StartPage><MedlinePgn>e2217199120</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2217199120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2217199120</ELocationID><Abstract><AbstractText>COVID-19 remains a global pandemic of an unprecedented magnitude with millions of people now developing "COVID lung fibrosis." Single-cell transcriptomics of lungs of patients with long COVID revealed a unique immune signature demonstrating the upregulation of key proinflammatory and innate immune effector genes CD47, IL-6, and JUN. We modeled the transition to lung fibrosis after COVID and profiled the immune response with single-cell mass cytometry in JUN mice. These studies revealed that COVID mediated chronic immune activation reminiscent to long COVID in humans. It was characterized by increased CD47, IL-6, and phospho-JUN&#xa0;(pJUN) expression which correlated with disease severity and pathogenic fibroblast populations. When we subsequently treated a humanized COVID lung fibrosis model by combined blockade of inflammation and fibrosis, we not only ameliorated fibrosis but also restored innate immune equilibrium indicating possible implications for clinical management of COVID lung fibrosis in patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Lu</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3531-8102</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Zhuoqing</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-7418-1313</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Pain and Perioperative Medicine, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Souza</LastName><ForeName>Cristabelle Madona</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerbs</LastName><ForeName>Tristan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Pain and Perioperative Medicine, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charu</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shih-Yu</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-7955-481X</Identifier><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissman</LastName><ForeName>Irving</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-9077-7467</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Center at Stanford University, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wernig</LastName><ForeName>Gerlinde</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5169-8731</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SPO182437</GrantID><Agency>Boehringer Ingelheim (BI)</Agency><Country/></Grant><Grant><GrantID>SPO134886</GrantID><Agency>National Scleroderma Foundation (SF)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051928">CD47 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Biotechnol. 2023 Apr;41(4):470. doi: 10.1038/s41587-023-01765-0</RefSource><PMID Version="1">37069391</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011658" MajorTopicYN="Y">Pulmonary Fibrosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051928" MajorTopicYN="N">CD47 Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">humanized mouse model</Keyword><Keyword MajorTopicYN="N">immune checkpoint therapy</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">long COVID pulmonary fibrosis</Keyword></KeywordList><CoiStatement>The authors have patent filings to disclose: I.W. and G.W. have patents that have been licensed, and it is possible that they could receive royalties from them. No current consultation with companies in this field. I.W. is a founder and director of Bitterroot Bio, Inc, Pheast, Inc, and 48 Bio, Inc, none of which has programs in this field.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>27</Day><Hour>15</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36848564</ArticleId><ArticleId IdType="pmc">PMC10013740</ArticleId><ArticleId IdType="doi">10.1073/pnas.2217199120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., et al. , Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497&#x2013;506 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing A. G., et al. , A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 26, 1623&#x2013;1635 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., et al. , Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 600, 523&#x2013;529 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348899</ArticleId><ArticleId IdType="pubmed">34634791</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., et al. , Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061&#x2013;1069 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tale S., et al. , Post-COVID-19 pneumonia pulmonary fibrosis. QJM 113, 837&#x2013;838 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454835</ArticleId><ArticleId IdType="pubmed">32814978</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwensen H. F., et al. , Fatal pulmonary fibrosis: A post-COVID-19 autopsy case. J. Clin. Pathol. 28, 206879 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32723800</ArticleId></ArticleIdList></Reference><Reference><Citation>Spagnolo P., et al. , Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet Respir. Med. 8, 750&#x2013;752 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228737</ArticleId><ArticleId IdType="pubmed">32422177</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazdyrev E., et al. , Lung fibrosis after COVID-19: Treatment prospects. Pharmaceuticals (Basel) 14, 807 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8398080</ArticleId><ArticleId IdType="pubmed">34451904</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown K. K., et al. , The natural history of progressive fibrosing interstitial lung diseases. Eur. Respir. J. 55, 2000085 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315005</ArticleId><ArticleId IdType="pubmed">32217654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynn T. A., Ramalingam T. R., Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat. Med. 18, 1028&#x2013;1040 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405917</ArticleId><ArticleId IdType="pubmed">22772564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson M. S., Wynn T. A., Pulmonary fibrosis: Pathogenesis, etiology and regulation. Mucosal Immunol. 2, 103&#x2013;121 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675823</ArticleId><ArticleId IdType="pubmed">19129758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynn T. A., Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199&#x2013;210 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693329</ArticleId><ArticleId IdType="pubmed">18161745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynn T. A., Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208, 1339&#x2013;1350 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136685</ArticleId><ArticleId IdType="pubmed">21727191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui L., et al. , Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity. Nat. Commun. 11, 2795 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270081</ArticleId><ArticleId IdType="pubmed">32493933</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam P. S., et al. , Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 1210&#x2013;1220 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., et al. , Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463&#x2013;469 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D., et al. , Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, eabc8511 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M., et al. , Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842&#x2013;844 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Schrepping J., et al. , Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 182, 1419&#x2013;1440.e23 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., et al. , Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature 599, 283&#x2013;289 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34517409</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant R. A., et al. , Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature 590, 635&#x2013;641 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987233</ArticleId><ArticleId IdType="pubmed">33429418</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon M. M. L., et al. , SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci. Immunol. 6, eabl9105 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626868</ArticleId><ArticleId IdType="pubmed">34618554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasenkrug K. J., et al. , Recovery from acute SARS-CoV-2 infection and development of anamnestic immune responses in T cell-depleted rhesus macaques. mBio 12, e0150321 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406331</ArticleId><ArticleId IdType="pubmed">34311582</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh W. C., et al. , NK cell receptor and ligand composition influences the clearance of SARS-CoV-2. J. Clin. Invest. 131, e146408 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553551</ArticleId><ArticleId IdType="pubmed">34720095</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharat A., et al. , Lung transplantation for patients with severe COVID-19. Sci. Transl. Med. 12, eabe4282 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8050952</ArticleId><ArticleId IdType="pubmed">33257409</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G., et al. , Persistent viral activity, cytokine storm, and lung fibrosis in a case of severe COVID-19. Clin. Transl. Med. 10, e224 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7607551</ArticleId><ArticleId IdType="pubmed">33252859</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyfman P. A., et al. , Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 199, 1517&#x2013;1536 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580683</ArticleId><ArticleId IdType="pubmed">30554520</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D. M., et al. , An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636&#x2013;1643 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Fontela C., et al. , Animal models for COVID-19. Nature 586, 509&#x2013;515 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8136862</ArticleId><ArticleId IdType="pubmed">32967005</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford K. H. D., et al. , Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12, 513 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7291041</ArticleId><ArticleId IdType="pubmed">32384820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolouri H., et al. , The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity. J. Clin. Invest. 131, e143648 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7843226</ArticleId><ArticleId IdType="pubmed">33529167</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., et al. , Post-acute COVID-19 syndrome. Nat. Med. 27, 601&#x2013;615 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D., Salah Eldin H., Taeimah M., Khattab R., Salem R., The COVID-19 cytokine storm; What we know so far. Front. Immunol. 11, 1446 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Fielding C. A., et al. , IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol. 181, 2189&#x2013;2195 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18641358</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume M., Higuchi Y., Uchiyama Y., Mihara M., IL-6 plays an essential role in neutrophilia under inflammation. Cytokine 54, 92&#x2013;99 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21292497</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernig G., et al. , Unifying mechanism for different fibrotic diseases. Proc. Natl. Acad. Sci. U.S.A. 114, 4757&#x2013;4762 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422830</ArticleId><ArticleId IdType="pubmed">28424250</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl A., et al. , Precision mouse models with expanded tropism for human pathogens. Nat. Biotechnol. 37, 1163&#x2013;1173 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776695</ArticleId><ArticleId IdType="pubmed">31451733</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl A., et al. , SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451&#x2013;457 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7979515</ArticleId><ArticleId IdType="pubmed">33561864</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>